Global News and Digital Insights
for the Healthcare Industry

French President Macron to unveil Novo Nordisk’s €2.1 Billion investment, signifying industrial revival

French President Emmanuel Macron is set to inaugurate a substantial 2.1 billion euro ($2.3 billion) investment by Novo Nordisk in France, signifying a resurgence in French industrial competitiveness. The Danish pharmaceutical company’s investment, centred in Chartres, near Paris, adds to its existing workforce of nearly 2,000 employees. Novo Nordisk, renowned for its widely-used anti-obesity drug Wegovy, will reportedly not provide specific details regarding the investment. The Elysee Palace touts this as Macron’s most significant healthcare sector investment, anticipating the creation of 500 new job opportunities. This substantial influx of capital signals a positive shift in France’s industrial landscape, positioning the country favourably and highlighting growing confidence in its healthcare industry.

Read more from Reuters
Facebook
Twitter
LinkedIn